Auto saved by Logseq

pages/STOP2030___Web___Posts.md

@@ -13,4 +13,45 @@
 	  
 	  If you want to review the full protocol, please visit the REALISE study's page at clinicaltrials.gov or PACTR.
 	  
-	  #+END_VERSE
+	  #+END_VERSE
+	- #
+	- # The REALISE clinical trial is registered
+	  
+	  At STOP2030, we aim to provide a pharmacological tool that aids in achieving the WHO's goals for
+	  soil-transmitted helminthiasis (STH) by 2030. That's why we are thrilled to announce that the REALISE study (Real world Evaluation of an ALbendazol-Ivermectin coformulation Safety and Effectiveness), our most ambitious clinical trial yet, has been registered on [clinicaltrials.gov](https://urldefense.com/v3/__https:/clinicaltrials.gov/study/NCT06282315__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncW8CTAdM$) and
+	  the [Pan African Clinical Trial
+	  Registry](https://urldefense.com/v3/__https:/pactr.samrc.ac.za/Search.aspx__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncACmxOT0$) (id number PACTR202402529220760). This news follows the
+	  approval from the Ghana Health Service Ethical Review Committee, obtained in
+	  December, 2023.
+	  
+	  
+	  
+	  This randomized control trial is a
+	  Cohort Event Monitoring study designed to evaluate the safety and effectiveness
+	  of our fixed-dose coformulation (FDC) of albendazole and ivermectin in large
+	  populations, compared to the standard dose of albendazole currently used
+	  against STH. We plan to recruit around 20,000 school-aged children between 5
+	  and 17 years old in Kenya and Ghana, starting in July 2024.
+	  
+	  
+	  
+	  The general goals of the REALISE
+	  study are to validate the benefits of the FDC through this pragmatic trial
+	  within the context of a mass drug administration (MDA) program, to evaluate
+	  safety as a primary endpoint, and effectiveness profile as a secondary
+	  endpoint, in a large population of school-aged children.
+	  
+	  
+	  
+	  The clinical trial will have two
+	  arms, randomized by school. One arm will receive a single dose of the
+	  fixed-dose coformulation tablet (alb 400mg/ivm 9mg for children between 5 and
+	  14 years old; alb 400mg/ivm 18mg for those aged 15-17), while the other arm,
+	  serving as an active control group, will receive a single dose of albendazole
+	  400mg, the current standard.
+	  
+	  
+	  
+	  If you want to review the full
+	  protocol, please visit the REALISE study's page on [clinicaltrials.gov](https://urldefense.com/v3/__http:/clinicaltrials.gov/__;!!MxJ9VFnHG7aJbmI!WQUMYoZBne-RmarvmmdxDOX3YMCZphl_SYR6TtQ550bOR1NSAz-QDjW71W8gqwBGC7emXh7iATor5zncV4ibvmQ$) or PACTR (trial id:
+	  PACTR202402529220760).